Borderline personality disorder: identification, comorbidity, and emerging treatment opportunities

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

This article analyses the diagnostic criteria for borderline personality disorder as defined in the 5th edition of Diagnostic and Statistical Manual of Mental Disorders and the 11th revision of International Classification of Diseases. The combination of categorical and dimensional diagnostic models improves its validity, which meets the needs of clinical practice. At the same time, the heterogeneity and persistent conceptual ambiguity of borderline personality disorder are emphasized. The phenomenology of comorbidity between borderline and addictive disorders is considered as overlapping symptoms that exacerbate overall clinical presentation. Challenges in diagnosing borderline personality disorder are noted when constitutional symptoms are masked by the consequences of psychoactive substance use. The article offers a brief overview of current approaches to the treatment of borderline personality disorder, highlighting the potential of ketamine therapy. The results of our own retrospective open study of 18 patients with dual (borderline personality disorder + alcohol/cocaine use disorder) and triple (borderline personality disorder + alcohol/cocaine use disorder + depression) diagnosis who received ketamine treatment are discussed. Patients received three ketamine infusions over one week (0.5–0.75 mg/kg over 40 minutes), followed by a booster session one month later. Preliminary results of treatment are discussed, which are quite comparable with the effectiveness of specialized psychotherapy. These findings suggest that ketamine therapy may offer a novel perspective on the traditionally pessimistic therapeutic outlook for borderline personality disorder.

About the authors

Mikhail L. Zobin

Centre of transformational therapy of addictions

Author for correspondence.
Email: dr.zobin@gmail.com
ORCID iD: 0000-0002-8239-3770
SPIN-code: 2440-1383

MD, Cand. Sci. (Medicine)

Russian Federation, Dobrota, Montenegro

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington: American Psychiatric Association; 2013. ISBN: 978-0-89042-554-1
  2. Leichsenring F, Fonagy P, Heim N, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23(1):4–25. doi: 10.1002/wps.21156
  3. WHO. ICD-11 Clinical descriptions and diagnostic guidelines for mental and behavioural disorders. Geneva: World Health Organisation; 2022. ISBN: 978-92-4-007726-3
  4. Bach B, Kramer U, Doering S, et al. The ICD-11 classification of personality disorders: a European perspective on challenges and opportunities. Bord Personal Disord Emot Dysregul. 2022;9(1):12. doi: 10.1186/s40479-022-00182-0
  5. Bohus M, Stoffers-Winterling J, Sharp C, et al. Borderline personality disorder. Lancet. 2021;398(10310):1528–1540. doi: 10.1016/S0140-6736(21)00476-1
  6. Gunderson JG, Herpertz SC, Skodol AE, et al. Borderline personality disorder. Nat Rev Dis Primers. 2018;4:18029. doi: 10.1038/nrdp.2018.29
  7. Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin N Am. 2018;41(4):583–593. doi: 10.1016/j.psc.2018.07.009
  8. Szerman N, Peris L. Personality disorders and addiction disorders. In: el-Guebaly N, Carrà G, Galanter M, editors. Textbook of Addiction Treatment: International Perspectives. Springer, Milano; 2015. Р. 2063–2083. doi: 10.1007/978-88-470-5322-9_120
  9. Trull TJ, Freeman LK, Vebares TJ, et al. Borderline personality disorder and substance use disorders: an updated review. Borderline Personal Disord Emot Dysregul. 2018;5:15. doi: 10.1186/s40479-018-0093-9
  10. Stetsiv K, McNamara IA, Nance M, Carpenter RW. The co-occurrence of personality disorders and substance use disorders. Curr Psychiatry Rep. 2023;25(11):545–554. doi: 10.1007/s11920-023-01452-6
  11. Szerman N, Torrens M, Maldonado R, et al. World association on dual disorders (WADD). addictive and other mental disorders: a call for a standardized definition of dual disorders. Transl Psychiatry. 2022;12(1):446. doi: 10.1038/s41398-022-02212-5
  12. Maremmani A, Maremmani I. It’s time to admit the existence of a psychopathology specific to addiction. Neurology Bulletin. 2025;57(1):5–11. doi: 10.17816/nb637368
  13. Chapman J, Jamil RT, Fleisher C, Torrico TJ. Borderline personality disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
  14. Trull TJ, Jahng S, Tomko RL, et al. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24(4):412–426. doi: 10.1521/pedi.2010.24.4.412
  15. Parmar A, Kaloiya G. Comorbidity of personality disorder among substance use disorder patients: a narrative review. Indian J Psychol Med. 2018;40(6):517–527. doi: 10.4103/IJPSYM.IJPSYM_164_18
  16. Jahng S, Trull TJ, Wood PK, et al. Distinguishing general and specific personality disorder features and implications for substance dependence comorbidity. J Abnorm Psychol. 2011;120(3):656–669. doi: 10.1037/a0023539
  17. Fraser R, Isaif L, Teles D, Laporte L. Personality disorders and addiction disorders. In: el-Guebaly N, Carrà G, Galanter M, Baldacchino AM, editors. Textbook of Addiction Treatment. Springer, Cham; 2021. doi: 10.1007/978-3-030-36391-8_96
  18. Mulder RT, Horwood LJ, Tyrer P. The borderline pattern descriptor in the International Classification of Diseases, 11th Revision: A redundant addition to classification. Aust N Z J Psychiatry. 2020;54(11):1095–1100. doi: 10.1177/0004867420951608
  19. Gutiérrez F, Aluja A, Ruiz Rodríguez J, et al. Borderline, where are you? A psychometric approach to the personality domains in the International Classification of Diseases, 11th Revision (ICD-11). Personal Disord. 2023;14(3):355–359. doi: 10.1037/per0000592
  20. Caspi A, Houts RM, Belsky DW, et al. The p factor: one general psychopathology factor in the structure of psychiatric disorders? Clin Psychol Sci. 2014;2(2):119–137. doi: 10.1177/2167702613497473
  21. Gluschkoff K, Jokela M, Rosenström T. General psychopathology factor and borderline personality disorder: Evidence for substantial overlap from two nationally representative surveys of U.S. adults. Personal Disord. 2021;12(1):86–92. doi: 10.1037/per0000405
  22. Sharp C, Wall K. DSM-5 level of personality functioning: refocusing personality disorder on what it means to be human. Annu Rev Clin Psychol. 2021;17:313-337. doi: 10.1146/annurev-clinpsy-081219-105402
  23. Zanarini MC, Temes CM, Frankenburg FR, et al. Description and prediction of time-to-attainment of excellent recovery for borderline patients followed prospectively for 20 years. Psychiatry Res. 2018;262:40–45. doi: 10.1016/j.psychres.2018.01.034
  24. Clinical guidelines: Specific personality disorders. 2024–2025–2026 (23.08.24). Approved by the Ministry of Health of the Russian Federation. (In Russ.) URL: http://disuria.ru/_ld/14/1459_kr24F60F61MZ.pdf
  25. National Institute for Health and Care Excellence. Borderline personality disorder: recognition and management. Clinical guideline. London: National Institute for Health and Care Excellence; 2009. URL: https://www.nice.org.uk/guidance/cg78
  26. Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregul. 2019;6:9. doi: 10.1186/s40479-019-0106-3
  27. Cristea IA, Gentili C, Cotet CD, et al. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(4):319–328. doi: 10.1001/jamapsychiatry.2016.4287
  28. Smits ML, Luyten P, Feenstra DJ, et al. Trauma and outcomes of mentalization-based therapy for individuals with borderline personality disorder. Am J Psychother. 2022;75(1):12–20. doi: 10.1176/appi.psychotherapy.20210027
  29. Setkowski K, Palantza C, van Ballegooijen W, et al. Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis. Psychol Med. 2023;53(8):3261–3280. doi: 10.1017/S0033291723000685
  30. Woodbridge J, Townsend M, Reis S, et al. Non-response to psychotherapy for borderline personality disorder: A systematic review. Aust N Z J Psychiatry. 2022;56(7):771–787. doi: 10.1177/00048674211046893
  31. Gartlehner G, Crotty K, Kennedy S, et al. Pharmacological treatments for borderline personality disorder: A systematic review and meta-analysis. CNS Drugs. 2021;35(10):1053–1067. doi: 10.1007/s40263-021-00855-4
  32. Stoffers J, Völlm BA, Rücker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653. doi: 10.1002/14651858.CD005653.pub2
  33. Pascual JC, Arias L, Soler J. Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs. 2023;37(6):489–497. doi: 10.1007/s40263-023-01015-6
  34. Yavi M, Lee H, Henter ID, et al. Ketamine treatment for depression: a review. Discov Ment Health. 2022;2(1):9. doi: 10.1007/s44192-022-00012-3
  35. Jones JL, Mateus CF, Malcolm RJ, et al. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:277. doi: 10.3389/fpsyt.2018.00277
  36. Dakwar E, Nunes EV, Hart CL, et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270–276. doi: 10.1016/j.neuropharm.2018.01.005
  37. Walsh Z, Mollaahmetoglu OM, Rootman J, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 2021;8(1):e19. doi: 10.1192/bjo.2021.1061
  38. Drozdz SJ, Goel A, McGarr MW, et al. Ketamine assisted psychotherapy: A systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706. doi: 10.2147/JPR.S360733
  39. Danayan K, Chisamore N, Rodrigues NB, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133. doi: 10.1016/j.psychres.2023.115133
  40. McIntyre RS, Lipsitz O, Rodrigues NB, et al. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord. 2020;22(8):831–840. doi: 10.1111/bdi.12941
  41. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. doi: 10.1176/ appi.ajp.2017.17060647
  42. Lengvenyte A, Olie E, Courtet P. Suicide has many faces, so does ketamine: a narrative review on Ketamine's antisuicidal actions. Curr Psychiatry Rep. 2019;21(12):132. doi: 10.1007/s11920-019-1108-y
  43. Nandan NK, Soni PK, Parsaik A, Hashmi A. "Esketamine" in borderline personality disorder: a look beyond suicidality. Cureus. 2022;14(4):e24632. doi: 10.7759/cureus.24632
  44. Rogg H, Avram M, Müller F, et al. Ketamine as a treatment option for severe borderline personality disorder: a case report. J Clin Psychopharmacol. 2023;43(1):64–65. doi: 10.1097/JCP.0000000000001642
  45. Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in borderline personality disorder. Neuropsychopharmacology. 2023;48(7):991–999. doi: 10.1038/s41386-023-01540-4
  46. Więdłocha M, Marcinowicz P, Komarnicki J, et al. Depression with comorbid borderline personality disorder — could ketamine be a treatment catalyst? Front Psychiatry. 2024;15:1398859. doi: 10.3389/fpsyt.2024.1398859
  47. Wöller W, Huppertz BJ. Borderline — eine diagnostische Einheit? [Borderline — a diagnostic entity?]. Fortschr Neurol Psychiatr. 1984;52(10):338–345. doi: 10.1055/s-2007-1002031
  48. Vanicek T, Unterholzner J, Lanzenberger R, et al. Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World J Biol Psychiatry. 2022;23(9):715–718. doi: 10.1080/15622975.2022.2031287
  49. Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year followup. J Subst Abuse Treat. 2002;23(4):273–283. doi: 10.1016/S0740-5472(02)00275-1
  50. Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol. 2021;35(2):150–158. doi: 10.1177/0269881120970879
  51. Chiappini S, d'Andrea G, De Filippis S, et al. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur Neuropsychopharmacol. 2023;74:15–21. doi: 10.1016/j.euroneuro.2023.04.01 145
  52. Mollaahmetoglu OM, Keeler J, Ashbullby KJ, et al. “This is something that changed my life”: A qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry. 2021;12:695335. doi: 10.3389/fpsyt.2021.695335
  53. Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol. 2018;9:132. doi: 10.3389/fphar.2018.00132
  54. Hutsebaut J, Bender DS. The clinical utility of the level of personality functioning scale: a treatment perspective. J Psychiatr Pract. 2024;30(6):411–420. doi: 10.1097/PRA.0000000000000822
  55. Kleindienst N, Jungkunz M, Bohus M. A proposed severity classification of borderline symptoms using the borderline symptom list (BSL-23). Borderline Personal Disord Emot Dysregul. 2020;7(1):11. doi: 10.1186/s40479-020-00126-6
  56. Unoka Z, Csáky-Pallavicini K, Horváth Z, et al. The Inventory of personality organization: A valid instrument to detect the severity of personality dysfunction. Front Psychiatry. 2022;13:995726. doi: 10.3389/fpsyt.2022.995726
  57. Gren J, Gorman I, Ruban A, et al. Call for evidence-based psychedelic integration. Exp Clin Psychopharmacol. 2024;32(2):129–135. doi: 10.1037/pha0000684
  58. Iliakis EA, Ilagan GS, Choi-Kain LW. Dropout rates from psychotherapy trials for borderline personality disorder: a meta-analysis. Personal Disord. 2021;12(3):193–206. doi: 10.1037/per0000453
  59. Leichsenring F, Sarrar L, Steinert C. Drop-outs in psychotherapy: a change of perspective. World Psychiatry. 2019;18(1):32–33. doi: 10.1002/wps.20588
  60. Sicorello M, Schmahl C. Emotion dysregulation in borderline personality disorder: A fronto-limbic imbalance? Curr Opin Psychol. 2021;37:114–120. doi: 10.1016/j.copsyc.2020.12.002
  61. Romeo B, Hermand M, Pétillion A, et al. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J Psychiatr Res. 2021;137:273–282. doi: 10.1016/j.jpsychires.2021.03.002
  62. Varela FJ, Thompson ET, Rosch E. The embodied mind: cognitive science and human experience. MIT press; 1993. 308 p.
  63. Davidson D. The material mind. Essays on actions and events. New York: Oxford University Press; 2001. 346 p.
  64. Tyrer P, Mulder R, Kim YR, Crawford MJ. The development of the ICD-11 classification of personality disorders: an amalgam of science, pragmatism, and politics. Annu Rev Clin Psychol. 2019;15:481–502. doi: 10.1146/annurev-clinpsy-050718-095736

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».